Deciphera Pharmaceuticals (DCPH) Prices 3.18M Share Common Offering at $55/Sh
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/6/2026
- S&P 500, Nasdaq close sharply higher as Broadcom rallies
- Oil prices settle at pre-Iran war levels as crude output grows
- Broadcom stock pops 4% as Apple silicon deal gets extended through 2031
- Buy the pullback in chip stocks, JPM's Matejka says
- Memory stocks rebound as analysts flag a buying opportunity
- Rivian Automotive (RIVN) files for 75M share offering
- Rivian offers Q2 2026 revenue outlook, cash position grows
- Nokia OYJ (NOKIA:FH) (NOK) PT Raised to EUR14 at Kepler Cheuvreux
- Meta capex to surge in 2027, neocloud fears ’erroneous’ - SemiAnalysis
- Broadcom secures role as key Apple supplier with chip deal through 2031
Deciphera Pharmaceuticals (DCPH) Announces FDA Acceptance of NDA and Priority Review for Ripretinib in Patients with Advanced Gastrointestinal Stromal Tumors
February 12, 2020 4:41 PM ESTDeciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) today announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review its New Drug Application (NDA) seeking approval for ripretinib, the Companys investigational broad-spectrum KIT and PDGFR inhibitor, for the treatment of patients with... More
Deciphera Pharmaceuticals (DCPH) to Offer $250M in Stock
February 12, 2020 4:15 PM ESTDeciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) announced the commencement of a registered underwritten public offering of $250.0 million in shares of its common stock. In addition, Deciphera intends to grant the underwriters a 30-day option to purchase up to $37.5 million in shares of its... More
